Correlation Engine 2.0
Clear Search sequence regions


  • DEGs (1)
  • dys (1)
  • glaucoma (3)
  • glucocorticoid (4)
  • human (5)
  • long term effect (1)
  • Rap1 (1)
  • rna (1)
  • study time (1)
  • trabecular meshwork (5)
  • Wnt (1)
  • Sizes of these terms reflect their relevance to your search.

    In the quest of identifying newer molecular targets for the management of glucocorticoid-induced ocular hypertension (GC-OHT) and glaucoma (GCG), several microarray studies have attempted to investigate the genome-wide transcriptome profiling of primary human trabecular meshwork (TM) cells in response to dexamethasone (DEX). However, no studies are reported so far to demonstrate the temporal changes in the expression of genes in the cultured human TM cells in response to DEX treatment. Therefore, in the present study, the time-dependent changes in the genome-wide expression of genes in primary human TM cells after short (16 hours: 16 h) and long exposure (7 days: 7 d) of DEX was investigated using RNA sequencing. There were 199 (118 up-regulated; 81 down-regulated) and 525 (119 up-regulated; 406 down-regulated) DEGs in 16 h and 7 d treatment groups respectively. The unique genes identified in 16 h and 7 d treatment groups were 152 and 478 respectively. This study found a distinct gene signature and pathways between two treatment regimes. Longer exposure of DEX treatment showed a dys-regulation of Wnt and Rap1 signaling and so highlighted potential therapeutic targets for pharmacological management of GC-OHT/glaucoma. © 2022. The Author(s).

    Citation

    Kandasamy Kathirvel, Karen Lester, Ravinarayanan Haribalaganesh, Ramasamy Krishnadas, Veerappan Muthukkaruppan, Brian Lane, David A Simpson, Kasia Goljanek-Whysall, Carl Sheridan, Devarajan Bharanidharan, Colin E Willoughby, Srinivasan Senthilkumari. Short and long-term effect of dexamethasone on the transcriptome profile of primary human trabecular meshwork cells in vitro. Scientific reports. 2022 May 18;12(1):8299

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 35585182

    View Full Text